Australia: TGA cancels Prexige registration over liver risks

08/12/2007 | MarketWatch

Australia's Therapeutic Goods Administration moved Saturday to cancel the registration of Novartis AG's pain drug Prexige after reports of liver damage risks surfaced. Prexige, a Cox-2 inhibitor similar to Vioxx, reportedly caused liver-related adverse reactions in the eight cases received by the TGA.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN